<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01172769</url>
  </required_header>
  <id_info>
    <org_study_id>HN001</org_study_id>
    <nct_id>NCT01172769</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Temsirolimus to Treat Head and Neck Cancer</brief_title>
  <acronym>TEMHEAD</acronym>
  <official_title>A Single Arm, Open-label Multicenter Phase II Trial of Temsirolimus in Patients With Relapsed/Recurrent Squamous Cell Cancer of the Head and Neck (HNSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether temsirolimus is effective in the treatment
      of relapsed/recurrent squamous cell cancer of the head and neck (HNSCC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), a crucial
      regulator of cell cycle progression. It was approved in the treatment of advanced renal cell
      carcinoma. Temsirolimus demonstrated also antitumor activity in a variety of other human
      cancer models, such as gliomas, rhabdomyosarcomas, neuroblastomas, prostata and breast
      cancer through induction of apoptosis or inhibition of proliferation. A similar effect was
      noted in HNSCC cell lines.

      This is the first study evaluating the efficacy and safety of temsirolimus in
      platinum/cetuximab-refractory HNSCC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Progression free rate</measure>
    <time_frame>at week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the patients free of progression (PFR) at week 12 based on CT or MRI scans evaluated according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>6 weeks (average)</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of temsirolimus</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>toxicity of temsirolimus are to be evaluated by CTC 3.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>at week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>objective response rate by RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.
Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered.</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Torisel</other_name>
    <other_name>mTOR inhibitor</other_name>
    <other_name>protein kinase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent must be given prior to study inclusion

          -  Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma
             of the head and neck (HNSCC)

          -  Measurable progressive disease after platinum-based radiochemotherapy or recurrence
             or metastatic progressive disease after 1st line platinum-based chemotherapy

          -  Patients with loco-regional recurrence need to be progression free for at least 6
             months after platinum-based radiochemotherapy, if locoregional recurrence is the only
             lesion

          -  Cetuximab must have been included in at least one prior line of therapy

          -  Disease is not amenable to surgery, radiotherapy or platinum-based chemotherapy

          -  At least one measurable lesion according to RECIST (Version 1.0) criteria

          -  Age &gt; 18 years

          -  ECOG performance status 0-2

          -  Brain metastases require completion of local therapy with discontinuation of steroids
             prior to start of treatment

          -  If of childbearing potential, willingness to use effective contraceptive method
             (double barrier method) for the study duration and 2 months after last dose

          -  Willingness and ability to comply with the protocol

          -  Adequate bone marrow function, liver and renal function

        Exclusion Criteria:

          -  Live expectancy less than 3 months

          -  Anticancer treatment during the last 30 days prior to start of treatment, including
             systemic therapy, radiotherapy or major surgery

          -  Participation in a clinical trial within the last 30 days prior to study treatment

          -  Serious illness or medical condition other than the disease under study

          -  Other malignancies within 3 years, with exception of HNSCC, history of a previous
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

          -  Inability to potentially complete follow up and treatment per protocol for
             psychological, familial, sociological or geographical reasons

          -  Pregnancy or breast feeding

          -  Known allergic/hypersensitivity reaction to any component of the treatment

          -  Concurrent treatment with oral anticoagulants

          -  Uncontrolled diabetes: fasting serum glucose &gt; 2.0 ULN

          -  Active or uncontrolled infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktor Gruenwald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical School Hannover</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viktor Gruenwald, MD</last_name>
    <phone>+ 49511 532-9196</phone>
    <phone_ext>or -4077</phone_ext>
    <email>Gruenwald.Viktor@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doris Behrens, MD</last_name>
    <phone>+ 49511 532-3596</phone>
    <email>behrens.doris@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charitè Berlin Campus Benjamin Franklin Medical Clinic III</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Keilholz, Prof MD</last_name>
      <phone>+4930-84453906</phone>
      <email>ulrich.keilholz@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Keilholz, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ev. Bethesda- Johanniter Klinikum GmbH Clinic for Heamatology and medical Oncology</name>
      <address>
        <city>Duisburg</city>
        <zip>47228</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Hennemann, Prof MD</last_name>
      <phone>+492065-971508</phone>
      <email>b.hennemann@johanniter-rheinhausen.de</email>
    </contact>
    <investigator>
      <last_name>Burkhard Hennemann, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen Clinic and Policlinic for internal medicine (Cancerresearch)</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gauler, MD</last_name>
      <phone>+49201-7233159</phone>
      <email>Thomas.gauler@uni-essen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Gauler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle Clinic and Policlinic of internal Medicine IV</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Joachim Schmoll, Prof. MD</last_name>
      <phone>+49345-5574959</phone>
      <email>joachim.schmoll@medizin.uni-halle.de</email>
    </contact>
    <investigator>
      <last_name>Hans-Joachim Schmoll, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical School Hannover Clinic for Heamatology, Hemostaseology, Oncology and stem cell transplantation</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Gruenwald, MD</last_name>
      <phone>+ 49511-532 9196</phone>
      <email>Gruenwald.Viktor@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Viktor Gruenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Clinic for Ear, Nose and Throat</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Guntinas Lichius, Prof. MD</last_name>
      <phone>+493641-935127</phone>
      <email>Orlando.Guntinas@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Orlando Guntinas Lichius, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig Clinic and Policlinic for Ear, Nose and Thorat</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Boehm, MD</last_name>
      <phone>+49341-9716301</phone>
      <email>andreas.boehm@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Boehm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>June 28, 2011</lastchanged_date>
  <firstreceived_date>July 7, 2010</firstreceived_date>
  <responsible_party>
    <name_title>MD Viktor Gruenwald</name_title>
    <organization>Medical School Hannover</organization>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Protein Kinase Inhibitors</mesh_term>
  </intervention_browse>
</clinical_study>
